Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older

This study of elderly patients with untreated DLBCL (n=249) found the addition of lenalidomide to R-miniCHOP (an attenuated dose of cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab) did not improve 2-year overall survival (65.7% v 66% R-miniCHOP; P=0.98).

Journal of Clinical Oncology